Skip to content
Screener

Organon OGN Other Women's Health — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M—
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

PBH
PBHWomen's Health — Total revenues
$52.54M-3.7%
Eli Lilly logo
LLYOther cardiometabolic health — Revenue
$1.03B+5.2%
Astrana Health logo
ASTHHealth Care Other — Revenue
$12.49M-13.8%
Omnicom Group logo
OMCHealth — Revenue
$586M+76.2%
Eli Lilly logo
LLYCardiometabolic Health — Revenue
$18.35B+61.8%
Cencora logo
CORAnimal Health — Revenue
$1.52B+3.3%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.56B+57.0%
Enterprise value$11.01B+4.2%
P/E6.6×+2.1×
P/S0.6×+0.2×

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Organon’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 8:46 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-029532
($ in millions)Three Months Ended March 31, 2025 / U.S.2025 / Int’lTotalU.S.Int’lTotal
Ganirelix Acetate Injection2242652327
Marvelon/Mercilon—2626—3939
Jada5—515—15
Other Women’s Health (1)173046152743
General Medicines
Biosimilars
Renflexis421557441257
Hadlima511667331447

Item 1. Financial Statements (unaudited)

FAQ

What is Organon's other women's health — revenue?
Organon (OGN) reported other women's health — revenue of $46M in Q1 2026.
How has Organon's other women's health — revenue changed year-over-year?
Organon's other women's health — revenue increased by 7.0% year-over-year, from $43M to $46M.
What is the long-term trend for Organon's other women's health — revenue?
Over 4 years (2021 to 2025), Organon's other women's health — revenue has grown at a -4.2% compound annual growth rate (CAGR), from $207M to $174M.
What does other women's health — revenue mean?
This metric represents the total net sales generated from the company's portfolio of women's health products that fall outside of its primary or core therapeutic focus areas. It serves as an indicator of the commercial performance and market demand for secondary reproductive and gynecological health offerings. Monitoring these revenues helps investors assess the contribution of niche or legacy women's health assets to the overall segment's top-line growth.

Ask your AI about Organon's other women's health — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude